Type 2 diabetes: A well-characterised but suboptimally controlled disease. Can we bridge the divide?

Diabetes and Metabolism

Volumn 34, Issue 3, 2008, Pages 207-216

  Monnier, L ^a   Colette, C ^a   Owens, D R ^b  

^a UNIV MONTPELLIER   (France)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Pathophysiology; Review; Therapy; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

BLOOD GLUCOSE MONITORING; CARBOHYDRATE METABOLISM; CIRCADIAN RHYTHM; COST BENEFIT ANALYSIS; DRUG COST; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; POSTPRANDIAL STATE; REVIEW; SELF MONITORING; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; METFORMIN; REFERENCE VALUES; THIAZOLIDINEDIONES;

EID: 49849089838     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2008.01.011     Document Type: Review

References (90)

1. Kannel W.B., and Mc Gee D.L. Diabetes and cardiovascular diseases: the Framingham study. JAMA 241 (1979) 2035-2038
2. Laakso M., and Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5 (1997) 294-315
3. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al., The UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
4. Colette C., and Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 39 (2007) 683-686
5. Monnier L., and Colette C. Glycemic variability. Should we and can we prevent it?. Diabetes Care 31 Suppl. 2 (2008) S150-S154
6. Clark Jr. C.M., Fradkin J.E., Hiss R.G., Lorenz R.A., Vinicor F., and Warren-Boulton E. The national diabetes education program, changing the way diabetes is treated. Diabetes Care 24 (2001) 617-618
7. Shojania K.G., Ranji S.R., Mac Donald K.M., Grimshaw J.M., Sundaream V., Rushakoff R.J., et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control. A meta-regression analysis. JAMA 296 (2006) 427-440
8. Boegner C, Fontbonne A, Gras-Vidal MF, Mouls P, Monnier L. Evaluation of a stuctured educational program for type 2 diabetes in private practice. Diabetes Metab 2008; 34, in press.
9. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl. 1 (2008) S12-S54
10. AFSSAPS-HAS. Type 2 diabetes treatment. French recommendations for good practice. Diabetes Metab 32 (2006) 643-648
11. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 29 (2006) 1963-1972
12. International Diabetes Federation Clinical guidelines task force. Guideline for type 2 diabetes. Brussels, IDF; 2005. p. 1-79.
13. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
14. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., et al. Addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357 (2007) 1716-1730
15. Nathan D.M. Finding new treatments for diabetes - how many, how fast... how good?. N Engl J Med 356 (2007) 437-440
16. Harris M.I., Eastman R.C., Cowie C.C., Flegal K.M., and Eberhardt M.C. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22 (1999) 403-408
17. Monnier L., Grimaldi A., Charbonnel B., Iannascoli F., Lery T., Garofano A., et al. Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory. Diabetes Metab 30 (2004) 35-42
18. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
19. Le Roith D. B-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113 (2002) 3S-11S
20. Khan S.E. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46 (2003) 3-19
21. De Fronzo R.A. Lilly lecture: the triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37 (1988) 667-687
22. De Fronzo R.A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5 (1997) 177-269
23. Levy J., Atkinson A.B., Bell P.M., Mac Cance D.R., and Hadden D.R. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast diet study. Diabet Med 15 (1998) 290-296
24. Monnier L., Colette C., Thuan J.-F., and Lapinski H. Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. Eur J Clin Invest 36 (2006) 231-235
25. Pratley R.E., and Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44 (2001) 929-945
26. UK Prospective Diabetes Study Group 16. Overview of 6 year's therapy for type 2 diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
27. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 38 (1995) 1378-1388
28. Boden G., Chen X., and Urbain J.L. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 45 (1996) 1044-1050
29. Radziuk J., and Pye S. Quantitation of basal endogenous glucose production in type II diabetes. Importance of the volume of distribution. Diabetologia 45 (2002) 1053-1084
30. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287 (2002) 360-372
31. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
32. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
33. Stumvoll M., and Jacob S. Multiple sites of insulin resistance: muscle, liver and adipose tissue. Exp Clin Endocrinol Diabetes 107 (1999) 97-106
34. Bolli G.B., and Gerich J.E. The dawn phenomenon: a common occurrence in both non insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 310 (1984) 746-750
35. De Fronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab 237 (1979) E214-E223
36. Pacy P.J., Cheng K.N., Thompson G.N., and Halliday D. Stable isotopes as tracers in clinical research. Ann Nutr Metab 33 (1989) 65-78
37. Shipley R.A., and Clark R.E. Tracer Methods for In Vivo Kinetics. Theory and Applications (1972), Academic Press, New York and London p. 1-239
38. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 24 (2001) 758-767
39. Monnier L., and Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 32 (2006) 7-13
40. Vilsbøll T., and Holst J.J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47 (2004) 357-366
41. Riddle M.C., and Drucker D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29 (2006) 435-449
42. Frias J.P., and Edelman S.V. Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes 14 (2007) 269-276
43. Rosenstock J., and Zinman B. Dipeptidyl peptidase-4 inhibitors and the management of diabetes mellitus. Curr opin Endocrinol Diabetes Obes 14 (2007) 98-107
44. Monnier L., Colette C., Dunseath G., and Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2007) 263-269
45. Yki-Järvinen H., Kauppinen-Mäkelin R., Tiikkainen M., Vähätalo M., Virtamo H., Nikkilä K., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET Study. Diabetologia 49 (2006) 442-451
46. Guillausseau P.J. Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents; value of evening blood glucose determination. Diabet Med 14 (1997) 798-802
47. Trovati M., Burzacca S., Mularoni E., Massuco P., Cavalot F., Mattiello L., et al. Occurence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycemic agents: importance of blood glucose monitoring. Diabetologia 34 (1991) 662-667
48. Monnier L., Colette C., and Lapinski H. Global assessment for quality and safety control in type 2 diabetic patients. Eur J Clin Invest 34 (2004) 37-42
49. Monnier L., Colette C., Boegner C., Pham T.C., Lapinski H., and Boniface H. Continuous glucose monitoring in patients with type 2 diabetes: why? when? whom?. Diabetes Metab 33 (2007) 247-252
50. De Fronzo R., Goodman AM, and The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333 (1995) 541-549
51. Cusi K., and De Fronzo R.A. Metformin: a review of its metabolic effects. Diabetes Rev 6 (1998) 89-131
52. Yki-Järvinenn H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
53. Lebovitz H.E. Insulin secretagogues: old and new. Diabetes Rev 7 (1999) 139-153
54. Culy C.R., Jarvis B., and Repaglinide. A review of its therapeutic use in type 2 diabetes. Drugs 61 (2001) 1625-1660
55. Owens D.R., Luzio S.D., Ismail I., and Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 23 (2000) 518-523
56. Owens D., Zinman B., and Bolli G. Insulins today and beyond. Lancet 358 (2001) 739-746
57. Hirsch I.B. Insulin analogs. N Engl J Med 352 (2005) 174-183
58. De Witt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus, scientific review. JAMA 289 (2003) 2254-2264
59. De Witt D.E., and Dugdale D.C. Using new insulin strategies in the outpatient treatment of diabetes. Clinical applications. JAMA 289 (2003) 2265-2269
60. Nathan D.M. Thiazolidinediones for initial treatment of type 2 diabetes. N Engl J Med 355 (2006) 2477-2480
61. Monnier L., Benichou M., Charra-Ebrard S., Boegner C., and Colette C. An overview of the rationale for the pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. Diabetes Metab 31 (2005) 101-109
62. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
63. Monnier L., Colette C., Rabasa-Lhoret R., Lapinski H., Caubel C., Avignon A., et al. Morning hyperglycemic excursions. A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 25 (2002) 737-741
64. Monnier L. Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?. Eur J Clin Invest 30 Suppl 2 (2000) 3-11
65. Monnier L., Avignon A., Virally M.L., Guillausseau P.J., and Sauvanet J.P. Les cycles glycémiques dans le diabète de type 2 : passé perdu ou retour vers le futur ?. Diabetes Metab 25 (1999) 526-531
66. Monnier L., and Colette C. Should seven be the magic number of type 2 diabetes?. Diabetologia 48 (2005) 1943-1944
67. Monnier L., Colette C., and Boniface H. Contribution of postprandial glucose to chronic hyperglycaemia: from the "glucose triad" to the trilogy of "sevens". Diabetes Metab 32 (2006) 2S11-2S16
68. Sacks D.B., Bruns D.F., Goldstein D.E., Maclaren N.K., Mac Donald J.M., and Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement). Diabetes Care 25 (2002) 750-786
69. Gorus F., Mathieu C., and Gerlo E. How should HbA1c measurements be reported?. Diabetologia 49 (2006) 7-10
70. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Diabetes Care 30 (2007) 2399-2400
71. Natali A., and Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49 (2006) 434-441
72. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26 (2003) 881-885
73. Monnier L., and Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 12 Suppl. 1 (2006) 42-46
74. Nauck M.A., Homberger E., Siegel E.G., Allen R.C., Earon R.P., Ebert R., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63 (1986) 492-498
75. Holst J.J. Glucagon-like peptide 1: physiology and therapeutic potential. Curr Opin Endocrinol Diabetes 12 (2005) 56-62
76. Sinclair E.M., and Drucker D.J. Glucagon-like peptide 1 agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabetes 12 (2005) 146-151
77. Breuer H.-W.M. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther 41 (2003) 421-440
78. Edelman S.V., Darsow T., and Frias J.P. Pramlintide in the treatment of diabetes. Int J Clin Pract 60 (2006) 1647-1653
79. Monnier L. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?. Nat Clin Pract Endocrinol Metab 3 (2007) 332-333
80. Creutzfeldt W.O., Kleine N., Willms B., Orskov C., Holst J.J., and Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type 1 diabetes. Diabetes Care 19 (1996) 580-586
81. Monnier L., Colette C., Lapinski H., and Boniface H. Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple. Diabetes Metab 30 (2004) 113-119
82. Saudek C.D., Derr R.L., and Kalyani R.R. Assessing glycemia in diabetes using self-monitoring blood glucose and HbA1c. JAMA 295 (2006) 1688-1697
83. Monnier L., Colette C., Boegner-Lemoine C., and Boniface H. Autosurveillance glycémique dans le diabète de type 1 et de type 2. Sang Thromb Vaiss 19 (2007) 467-472
84. Dinneen S., Gerich J.E., and Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 327 (1992) 707-713
85. Wolever T.M., Yang M., Zeng X.Y., Atkinson F., and Brand-Miller J.C. Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals. Am J Clin Nutr 83 (2006) 1306-1312
86. Jaber L.A., Antal E.J., Slaughter R.L., and Welshman I.R. Comparison of pharmacokinetics and pharmacodynamics of short and long-term glyburide therapy in NIDDM. Diabetes Care 11 (1994) 1300-1306
87. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients. Horm Metab Res 28 (1996) 434-439
88. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vicenzo A., et al. Pharmaco-kinetics and pharmacodynamics of subcutaneaous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
89. Owens D., Coates P., Luzio S., Tinbergen J., and Kurzhals R. Pharmacokinetics of [125]I-labelled insulin glargine (HOE 901) in healthy men. Diabetes Care 23 (2000) 813-819
90. Heise T., Nosek L., Ronn B.B., Endahl L., Heinemann L., Kapitza C., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620